InvestorsHub Logo
Post# of 252713
Next 10
Followers 834
Posts 120144
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 2319

Tuesday, 06/22/2004 3:02:26 AM

Tuesday, June 22, 2004 3:02:26 AM

Post# of 252713
Interview with Cortex's Roger Stoll,
in the Wall Street Transcript:


http://www.cortexpharm.com/pdfs/2-InterviewCOR2004.pdf

This interview, from May, 2004, contains a frank discussion of what went wrong with COR’s initial Ampakine compound, CX-516, and why the follow-on molecule, CX-717, should work a heck of a lot better. A pretty good overview of this promising --and exceptionally cheap-- company in the CNS arena.

It’s instructive to compare this TWST interview with one from last summer (#msg-3202870) to see just what has changed in the ensuing ten months.

[Thanks to ‘apoolfool’ on the Yahoo board.]

P.S. COR has a 30-minute webcast today (Tuesday):
http://biz.yahoo.com/cc/3/43473.html




“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.